All conditions

Irritable Bowel Syndrome

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

1026
Trials on record
106
Recruiting now
2
Australian sites
9
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Irritable Bowel Syndrome →

Get alerts when Irritable Bowel Syndrome trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome, often called IBS, is a condition that affects how the large intestine (bowel) works. People with IBS commonly experience symptoms like stomach pain or cramping, bloating, and changes in their bowel habits — this might mean diarrhoea, constipation, or sometimes both at different times. Importantly, IBS does not damage the bowel or increase the risk of serious bowel diseases. Doctors believe it involves a disconnect between the brain and the gut, meaning the digestive system can become oversensitive or react in unusual ways, though the exact cause is not fully understood.

IBS is very common in Australia. Roughly one in five Australians will experience it at some point in their life, and it affects people of all ages, including children and older adults. It tends to be more commonly diagnosed in women than men. Many people find that certain foods, stress, hormonal changes, or illness can trigger or worsen their symptoms. Because symptoms can vary so much from person to person, two people with IBS may have quite different experiences of the condition.

When it comes to managing IBS, there is no single approach that works for everyone, and treatment is generally focused on reducing symptoms and improving day-to-day comfort. Common approaches that doctors discuss with patients include dietary changes — such as adjusting fibre intake or trialling a low-FODMAP diet under professional guidance — stress management techniques, and in some cases medication. A GP or gastroenterologist will usually work with a patient over time to figure out what combination of strategies suits them best.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Irritable Bowel Syndrome in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Irritable Bowel Syndrome currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Irritable Bowel Syndrome.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Irritable Bowel Syndrome by country. Australia is highlighted.

Showing the top 10 of 42 countries with trial sites.

Clinical trials for Irritable Bowel Syndrome

Showing 109 of 109 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT01880424 · AstraZeneca Phase 3 · 5 countries Completed
Completed Phase 3 Est. completion 1 May 2015
🇦🇺 AU🇨🇦 CA🇨🇳 CN🇳🇿 NZ🇺🇸 US

**Who might be able to join this trial:** - You have read, understood, and signed a consent form agreeing to take part in the study. - You are not currently pregnant or breastfeeding, and you are willing to use birth control during the study. - You meet the requirements for having a colonoscopy as set out by a major ga...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05274854 · The University of Queensland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2025
🇦🇺 AU

**Who might be able to join this trial:** - People who have ongoing or recurring digestive or gut symptoms that are not considered urgent or dangerous, and who are already on the waiting list for an integrated care clinic. - People whose gut symptoms are considered severe, based on a score above 35 on a specific sympto...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06940596 · University of Melbourne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇦🇺 AU

**Who might be able to join this trial:** - You currently live in Australia or the United States - You are 18 years of age or older - Your Body Mass Index (BMI) falls between 18.5 and 34.9 (confirm with trial site if unsure of your BMI) - You have been diagnosed with Irritable Bowel Syndrome (IBS) by a doctor or speci...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT01199302 · Amgen Phase 2 · 8 countries Terminated
Terminated Phase 2 Est. completion 18 October 2011
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇷 FR🇳🇱 NL🇵🇱 PL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who were enrolled in the related earlier study (NCT01150890) and completed their Week 12 check-up in that study. - People whose Week 12 check-up in the earlier study took place no more than 1 year before the planned start date in this trial. - The person joining, or t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02641392 · Celgene Phase 3 · 31 countries Terminated
Terminated Phase 3 Est. completion 4 January 2018
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇬 BG🇨🇦 CA🇭🇷 HR🇨🇿 CZ🇩🇰 DK +23 more

**Who might be able to join this trial:** - You are 18 years of age or older (for adult participants) - You previously took part in a specific related clinical study called GED-0301-CD-002 or GED-0301-CD-003 - You are willing and able to use an approved method of contraception as required by the study - You are betwee...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01762579 · University of Palermo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2016
🇮🇹 IT

**Who might be able to join this trial:** - You are an adult aged between 18 and 65 years old (any gender) - You have symptoms similar to Irritable Bowel Syndrome (IBS), such as digestive discomfort or bowel problems - Your symptoms got better when you stopped eating gluten, and got worse when you started eating gluten...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01912313 · KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇧🇪 BE

Who might be able to join this trial: - People who have been diagnosed with Irritable Bowel Syndrome (IBS), based on a standard set of medical guidelines called the Rome III Criteria - People who are generally healthy (without IBS) Who may not be able to join: - People whose health complaints or symptoms are not relat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02421705 · KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2099
🇧🇪 BE

**Who might be able to join this trial:** - People who have been diagnosed with Irritable Bowel Syndrome (IBS) based on a standard set of medical criteria (called ROME III), with no other clear medical reason found for their symptoms (Group 1) - People who have been diagnosed with active ulcerative colitis, confirmed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03223077 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

Who might be able to join this trial: - You have not had any abdominal (stomach area) surgery, except for removal of the appendix or gallbladder - You have been diagnosed with a gut infection caused by Campylobacter bacteria, confirmed by a stool (poo) test Who may not be able to join: - You have a history of irritabl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03339128 · AbbVie Phase 2 · 9 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇧🇬 BG🇨🇦 CA🇩🇪 DE🇭🇺 HU🇳🇱 NL🇵🇱 PL🇪🇸 ES🇬🇧 GB +1 more

**Who might be able to join this trial:** - The participant (and their parent, guardian, or legal representative) must agree to take part and sign the required consent forms before any study procedures begin. - The participant must be a male or female aged 6 to 17 years (inclusive) who is being treated as an outpatien...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03613545 · Guangzhou First People's Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - You must be able to read and sign a consent form agreeing to take part in the study. - You must be male or female, aged between 18 and 75 years old. - You must have been diagnosed with Irritable Bowel Syndrome (IBS) based on a specific set of recognised medical guidelines called...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03687814 · University of Michigan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older. - You have been diagnosed with or meet the criteria for IBS with constipation (IBS-C), meaning you have recurring stomach pain at least one day per week on average over the past 3 months, and that pain is linked to going to the bathroom, changes...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04217733 · Tanta University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2030
🇪🇬 EG

Who might be able to join this trial: - You must be 18 years of age or older - Both men and women can participate, but women must have a negative pregnancy test and be using effective contraception - You must have been diagnosed with Irritable Bowel Syndrome (IBS) according to a standard set of medical guidelines calle...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04506593 · Indiana University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

Who might be able to join this trial: - You must be a patient seen at a gastroenterology clinic, hospital consultation service, or outpatient endoscopy center within the Division of Gastroenterology and Hepatology - You must have been diagnosed with a digestive system motility disorder (a condition where food or waste...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04918329 · University Hospital, Rouen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 October 2030
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 years or older - People who have had a functional digestive disorder (a long-term condition affecting how the digestive system works) for more than 3 months - People who are already being seen as part of their regular medical care - People who are enrolled in the F...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04974593 · Universitair Ziekenhuis Brussel Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2028
🇧🇪 BE

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) according to a standard set of medical guidelines called the ROME IV criteria - Your IBS symptoms are at least moderate in severity, based on a specific symptom scoring system (confirm with trial site) - You regularl...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05097872 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇧🇪 BE

**Who might be able to join this trial:** - You are between 18 and 70 years old (including age 70) - You are male or female - You have been diagnosed with IBS with diarrhea (IBS-D) or IBS with mixed bowel habits (IBS-M), based on specific diagnostic guidelines called Rome IV criteria - Your IBS symptoms are moderate t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05120752 · Universitair Ziekenhuis Brussel Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2028
🇧🇪 BE

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with Irritable Bowel Syndrome (IBS) based on a specific set of standard medical guidelines called the Rome IV criteria - Your IBS symptoms are at a moderate level of severity, based on a specific symptom scoring sy...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05185609 · Region Örebro County Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇸🇪 SE

Who might be able to join this trial: - Healthy volunteers with no digestive or other major health conditions - People with moderate to severe IBD (such as Crohn's disease or ulcerative colitis) whose disease is currently in remission but who still experience ongoing symptoms - People with moderate to severe IBD whose...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05293769 · Universitair Ziekenhuis Brussel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇧🇪 BE

**Who might be able to join this trial:** - People between 18 and 65 years old - People who are willing and able to sign a written consent form - People who are currently living in Belgium **Who may not be able to join:** - People who have followed a diet in the 8 weeks before joining the trial - People who have a kno...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05361785 · Helsinki University Central Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2024
🇫🇮 FI

**Who might be able to join this trial:** - You are between 18 and 75 years old and can understand Finnish - You have been diagnosed with Irritable Bowel Syndrome (IBS) using a specific standard set of diagnostic criteria called Rome IV (all types of IBS are accepted) - You are currently using a low FODMAP diet (a spec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05519683 · University of Michigan Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome with Constipation (IBS-C) and are currently experiencing symptoms. - Your abdominal pain reaches a significant level of severity during a lead-in monitoring period before the trial begins (the exact level is defined by th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05652621 · The First Affiliated Hospital of Xinxiang Medical College Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2024
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed by a doctor with ulcerative colitis - You have been diagnosed by a doctor with irritable bowel (also known as irritable bowel syndrome or IBS) - You are able to swallow small probiotic pellets as required by the study Who may not be able to join: - You ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05680766 · Universitair Ziekenhuis Brussel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 January 2030
🇧🇪 BE

**Who might be able to join this trial:** - People between 18 and 60 years old - People who have been diagnosed with Irritable Bowel Syndrome (IBS) according to a standard set of medical guidelines called the ROME IV criteria - People whose IBS symptoms are rated as moderate or above, based on a specific IBS symptom sc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05719246 · The Cooper Health System Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - You must be a patient of the Cooper Pediatric Gastroenterology practice in Camden, NJ or Voorhees, NJ - You must be between 12 and 21 years old - You must have been diagnosed with any type of Irritable Bowel Syndrome (IBS) - You must have access to the internet so you can watch y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05721742 · Nova Scotia Health Authority Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇨🇦 CA

Who might be able to join this trial: - You have had recurring stomach pain at least one day per week on average over the last 3 months, and this pain is connected to at least two of the following: going to the toilet, changes in how often you have bowel movements, or changes in what your stools look like - You are wil...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05730491 · Seattle Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇺🇸 US

**Who might be able to join this trial:** - The parent or caregiver taking part must be at least 18 years old - The parent has been diagnosed with IBS (irritable bowel syndrome) or unexplained stomach pain in the last five years, OR they regularly experience stomach pain at least once a week that is linked to changes i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05740319 · Shanghai Zhongshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) and are between 18 and 70 years old - You have already tried at least 3 standard treatments for IBS without success - You do not have warning signs such as unexplained weight loss or blood in your stool **Who may no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05776914 · Madhusudan (Madhu) Grover, MBBS Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 26 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) according to a specific standard set of medical guidelines called the Rome IV criteria. - Your IBS is not the type that mainly causes constipation (known as IBS-C). - Your IBS symptoms are moderate to severe, based...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05796388 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 70 years old (men and women) who have been diagnosed with a type of irritable bowel syndrome that involves mainly constipation (IBS-C), based on a standard set of medical guidelines called Rome IV criteria. - People whose IBS significantly affects their...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05803980 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 September 2025
🇮🇹 IT

**Who might be able to join this trial:** - You are able to understand and sign a consent form agreeing to take part - You are 18 years old or older - You have been diagnosed with diarrhoea-predominant or unclassified IBS (irritable bowel syndrome), based on a standard set of diagnostic guidelines called Rome IV criter...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05803993 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 September 2025
🇮🇹 IT

**Who might be able to join this trial:** - You are able to understand and sign a consent form agreeing to take part in the study - You are 18 years old or older - You have been diagnosed with irritable bowel syndrome (IBS) where constipation is the main symptom, or where your bowel habits alternate between constipatio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05808036 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇧🇪 BE

**Who might be able to join this trial:** - You are willing to take part and have given your written agreement to join before any checks begin. - You are using a reliable form of birth control (such as implants, injections, the pill, certain coils, or complete abstinence from sex) or have a partner who has had a vasec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05815602 · Guy Boeckxstaens Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2027
🇧🇪 BE

**Who might be able to join this trial:** - You are willing to give written consent to take part before any screening begins - You have been diagnosed with Irritable Bowel Syndrome (IBS) that does not involve mainly constipation, based on standard medical criteria called Rome IV - Tests have ruled out other conditions...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05972291 · VA Office of Research and Development Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You are a Veteran between 18 and 65 years old who has been diagnosed with Gulf War Illness (GWI) and have ongoing stomach problems such as abdominal pain, diarrhea, or bloating - Your stomach symptoms began during your deployment in the Persian Gulf (confirm with trial site i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05972317 · Weizmann Institute of Science Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇮🇱 IL

Who might be able to join this trial: - You are male or female - You are between 18 and 70 years old Who may not be able to join: - You have taken antibiotics in the 2 months before the trial starts - You have taken probiotic supplements (such as probiotic pills or powders) in the month before the trial starts - You h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06090110 · Maastricht University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with Irritable Bowel Syndrome (IBS) based on a specific set of medical guidelines called the Rome IV criteria, which means having recurring stomach pain at least one day per week on average over the last 3 months, linked to two or more of the f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06104631 · Biokuris s.a. Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇧🇪 BE🇫🇷 FR

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with Crohn's disease and have been in remission (no active flare-up) for more than 3 months without using steroids - Your doctor considers your Crohn's disease to currently be in remission - Your blood or other te...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06211062 · Nova Southeastern University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 24 February 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) according to specific medical guidelines called the IOM criteria (confirm with trial site) - You also have Irritable Bowel Syndrome (IBS) — specifically the type where you experience both...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06215222 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 70 years old at the time of the first screening visit. - People who are generally healthy or have only a mild health condition (as assessed by an anaesthesiology health rating scale). - Women who could become pregnant must have a negative pregnancy test with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06247046 · Guangzhou Zhiyi Biotechnology Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a consent form, follow the study rules, and complete a daily diary throughout the trial. - People aged 18 to 70 years old (any gender). - People who have been diagnosed with diarrhoea-predominant irritable bowel syndrome (IBS-D) based on recogn...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06268964 · Universidad de Colima Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2024
🇲🇽 MX

Who might be able to join this trial: - Children and teenagers between 4 and 18 years old. - Those who have been diagnosed with a functional abdominal pain condition (such as Functional Dyspepsia, Irritable Bowel Syndrome, Abdominal Migraine, or Functional Abdominal Pain Not Otherwise Specified) based on a standard set...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06271538 · EP Plus Group Sdn Bhd Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 March 2026
🇲🇾 MY

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) using a standard set of diagnostic guidelines called the Rome IV criteria - You are 18 years of age or older (any gender can apply) - You have any type of IBS, whether it mainly causes diarrhea, constipation, or a mi...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06288672 · IBS-80, LLC Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with Irritable Bowel Syndrome (IBS) by a primary care doctor, gut specialist, or allergy specialist - People whose IBS symptoms are not well controlled and who meet a standard set of IBS diagnostic guidelines called the Rome IV criteria (confirm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06291038 · University Hospital, Rouen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2029
🇫🇷 FR

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with diarrhea-predominant irritable bowel syndrome (IBS-D), confirmed using a standard set of medical criteria called Rome IV - Your IBS symptoms are moderate to severe, based on a specific symptom score (Francis s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06317441 · Nimble Science Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 to 65 years old, of any gender. - People who are willing and able to sign a consent form and follow the study procedures. - People who are willing to keep their diet and physical activity the same throughout the study. - People who are able to swallow a large...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06369753 · Hospital Universitari Vall d'Hebron Research Institute Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇨🇦 CA🇫🇷 FR🇮🇹 IT🇪🇸 ES🇸🇪 SE🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You experience episodes of visible stomach bloating (where your belly visibly swells) that are triggered by eating a meal Who may not be able to join: - A physical or medical cause for your symptoms has been found through medical tests or examinations - You suffer from constipat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06381921 · University of Connecticut Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Irritable Bowel Syndrome (IBS) by a doctor using standard diagnostic guidelines, and you currently experience stomach pain - You are a man or woman between 18 and 50 years old - You are able to read and speak English - You have daily access to a compu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06413004 · Magnus Simrén Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇸🇪 SE

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) by your doctor, using a standard set of diagnostic guidelines. - You notice that eating food triggers your gut or digestive symptoms. - You are able and willing to sign a consent form before any study activities begi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06473454 · Istanbul Saglik Bilimleri University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2024
Turkey (Türkiye)

**Who might be able to join this trial:** - You are between 18 and 65 years old - You meet a specific set of guidelines used to diagnose irritable bowel syndrome or similar gut conditions, known as the Rome IV criteria (confirm with trial site) - You are willing to take part and can sign a written consent form **Who m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06489444 · Second Affiliated Hospital of Xi'an Jiaotong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2024
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) based on specific medical guidelines (called Rome IV criteria), meaning you have recurring stomach pain at least 1 day per week on average over the last 3 months, along with 2 or more of the following: pain related t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06551961 · University of Nottingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇬🇧 GB

**Who might be able to join this trial:** - You are between 18 and 65 years old. - You are able to understand and agree to take part in the study (give informed consent). - Your gut symptoms (such as gas, bloating, stomach pain, loose stools, or hard stools) have been mild or very minor over the past 2 weeks, based on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06612411 · Jinling Hospital, China Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS), confirmed using a standard set of diagnostic guidelines called the Rome IV criteria - You are between 16 and 80 years old - You do not have other gut or bowel conditions such as inflammatory bowel disease, infectiou...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06636513 · Changi General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2025
🇸🇬 SG

**Who might be able to join this trial:** - People aged between 21 and 70 years old (male or female) - People who have been diagnosed with Irritable Bowel Syndrome with diarrhoea (IBS-D), mixed-type IBS (IBS-M), or functional diarrhoea, according to specific medical criteria called the Rome III definition — this invol...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06639984 · Dr Bruno Chumpitazi, M.D. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - Children who are between 12 and 17 years old and have been diagnosed with Irritable Bowel Syndrome (IBS) based on a specific set of medical guidelines called the Pediatric Rome IV criteria **Who may not be able to join:** - Children who have had surgery on their bowels, have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06647043 · Universiti Sains Malaysia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇲🇾 MY

**Who might be able to join this trial:** - You are male or female, aged between 18 and 70 years old - You have been diagnosed with Irritable Bowel Syndrome (IBS) with diarrhoea or mixed bowel habits, based on having stomach pain or discomfort at least 3 days per month for the last 3 months, with symptoms starting at l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06665867 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2025
🇳🇱 NL

Who might be able to join this trial: - Children between the ages of 4 and 17 years old - Children who have been diagnosed with one of four types of functional abdominal pain conditions (stomach pain that has no clear physical cause), including functional dyspepsia, irritable bowel syndrome, abdominal migraine, or gene...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06668922 · University of California, Los Angeles Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 75 years old - People who have been diagnosed with irritable bowel syndrome (IBS) - Healthy volunteers who have no history of gut or digestive diseases or symptoms - People who do not follow any special diet, except vegetarians, who may still be eligible (co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06681012 · Devintec Sagl Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇧🇪 BE🇫🇷 FR🇮🇹 IT🇪🇸 ES

**Who might be able to join this trial:** - You are between 18 and 65 years old (male or female) - You have been diagnosed with Irritable Bowel Syndrome (IBS) following recognised medical guidelines, meaning you have had recurring stomach pain at least once a week for the past 3 months, linked to changes in your bowel...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06684470 · Mayo Clinic Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 19 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 70 years old - You have scored above 175 on a questionnaire that measures the severity of IBS symptoms (called the IBS-SSS) - You have been diagnosed with a specific type of IBS that mainly involves diarrhea, according to recognised medical guidelines (...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06705153 · Ataturk University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 January 2025
Turkey (Türkiye)

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) using a standard set of medical guidelines called the Rome IV criteria - You score 75 or above on a standard IBS symptom severity questionnaire (confirm with trial site) - You score at certain levels on a standard qu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06719778 · Universität Duisburg-Essen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇩🇪 DE

**Who might be able to join this trial:** - You are over 18 years old - You have been diagnosed with Crohn's Disease for at least 6 months - You have had moderate to severe symptoms that seem to be triggered by food, or symptoms similar to irritable bowel syndrome (IBS), for at least 3 months - Your Crohn's Disease med...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06721624 · National University of Natural Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older and have already been diagnosed with Irritable Bowel Syndrome (IBS), or you have gut/digestive symptoms that are similar to IBS. - The main reason for your medical visit is your IBS diagnosis or your IBS-like digestive symptoms. - Your IBS diagnos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06727422 · Mark Pimentel, MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You are male, or a female who is not pregnant or breastfeeding, and you are 18 years of age or older - You have been diagnosed with Irritable Bowel Syndrome (IBS) using a standard set of diagnostic guidelines called the Rome IV criteria - Your IBS symptoms — including abdomin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06737666 · Xiyuan Hospital of China Academy of Chinese Medical Sciences Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 8 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with diarrhea-predominant irritable bowel syndrome (IBS-D), as well as healthy volunteers who meet the study's diagnostic criteria - People aged between 18 and 70 years old - People who have not taken antibiotics, steroids or other hormones, herbal preparatio...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06749613 · Attikon Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 October 2025
🇬🇷 GR

Who might be able to join this trial: - People who are willing and able to give written consent to participate. - People who are available and able to attend throughout the entire study period. - People who were previously diagnosed with IBS (diarrhoea-type, mixed-type, or unclassified-type) and took part in an earlier...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06757491 · The First Affiliated Hospital of Soochow University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 December 2025
🇨🇳 CN

Who might be able to join this trial: - Adults aged between 18 and 75 years - People diagnosed with diarrhoea-predominant irritable bowel syndrome (IBS-D) according to a standard set of medical guidelines called the Rome IV criteria, confirmed by a specialist stomach and bowel doctor Who may not be able to join: - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06783894 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2025
🇪🇬 EG

Who might be able to join this trial: - Men who have been diagnosed with irritable bowel syndrome (a condition that causes stomach pain and changes in bowel habits) - Men who have been diagnosed with erectile dysfunction (difficulty getting or maintaining an erection) - Men who are married Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06788444 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 60 years old - You have been rated as generally healthy or having only mild health conditions by a doctor's standard health assessment (confirm with trial site) - Your Body Mass Index (BMI) is between 15 and 30 (a measure of weight relative to height) -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06801184 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 October 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with Irritable Bowel Syndrome (IBS) — a condition causing ongoing stomach pain at least once a week over the past 3 months, linked to bowel habits such as changes in how often someone goes to the toilet or changes in stool texture - People whos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06847360 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 29 years old - You can be a man or a woman - A healthcare provider has diagnosed you with Irritable Bowel Syndrome (IBS), and you will need to bring proof of this diagnosis to your first appointment - You currently experience IBS-related pain that is at lea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06866106 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇺🇸 US

Who might be able to join this trial: - Adults who have been diagnosed with Irritable Bowel Syndrome (IBS) that meets a standard set of diagnostic guidelines called the Rome IV criteria. - People who are fluent in English and have access to a phone. Who may not be able to join: - People who have inflammatory bowel dis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06900491 · University Hospital, Rouen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 September 2030
🇫🇷 FR

**Who might be able to join this trial:** - People who are 18 years of age or older - People whose routine blood test results (including full blood count and inflammation markers) are within normal range - People who are enrolled in a French social security scheme - People who have read and understood the study informa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06912828 · Attikon Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2026
🇬🇷 GR

Who might be able to join this trial: - You have been diagnosed with Irritable Bowel Syndrome (IBS) based on a standard set of recognised diagnostic guidelines called the Rome IV criteria - You are willing and able to sign a consent form agreeing to take part in the study - You are able to commit to being available and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06917963 · Medical University of Gdansk Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇵🇱 PL

Who might be able to join this trial: - You are 18 years of age or older - You are scheduled to have planned or emergency surgery that will result in the creation of an ileostomy (a surgically made opening from the small intestine through the belly, either as a loop or end opening) - You are able and willing to sign a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06923800 · Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bell... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇮🇹 IT

Who might be able to join this trial: - You have been formally diagnosed with both Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM), confirmed using standard medical guidelines. - Your IBS symptoms are rated as moderate to severe, based on a standard IBS symptom scoring system (confirm with trial site). - You are a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06960369 · The First Affiliated Hospital of Soochow University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) according to specific standard diagnostic guidelines called the Rome IV criteria. - You are between 18 and 70 years old. - You have had IBS symptoms for more than 6 months. - Tests have not found any physical or che...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07000227 · Universiti Kebangsaan Malaysia Medical Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇲🇾 MY

Who might be able to join this trial: - People aged 18 or older - People who are able to give their informed agreement to take part in the trial - People who have already been assessed by a gut specialist (gastroenterologist) and have irritable bowel syndrome (IBS), functional dyspepsia (a condition causing ongoing sto...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07000383 · University Medical Center Ho Chi Minh City (UMC) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2026
🇻🇳 VN

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with a specific type of irritable bowel syndrome called IBS-D (diarrhoea-predominant), confirmed using a recognised set of medical guidelines called the Rome IV criteria — this means having recurring stomach pain...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07039747 · University Hospital, Rouen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with Irritable Bowel Syndrome (IBS) according to a standard diagnostic framework called the Rome IV criteria - People aged between 18 and 75 years - People whose IBS symptoms are above a certain level of severity, as measured by a standard scori...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07094035 · Adamas Biotech S.r.l. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇮🇹 IT

Who might be able to join this trial: - People aged between 18 and 70 years - People who are able to understand and sign a consent form agreeing to take part - People who have tested negative for HIV - People who have tested negative for pregnancy - People who have had irritable bowel syndrome (IBS) symptoms for at lea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07114055 · Md. Hazrat Ali Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2026
Bangladesh

**Who might be able to join this trial:** - You must be 18 years of age or older - You must have been diagnosed with a type of irritable bowel syndrome that mainly causes diarrhea (known as IBS-D), based on a specific set of recognised medical guidelines called the Rome IV criteria (confirm with trial site) **Who may...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07145580 · Klinik Arlesheim Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇭 CH

Who might be able to join this trial: - You were referred for a breath test to help find out the cause of digestive symptoms or difficulty digesting food, between 2020 and 2024 - You have signed a general consent form allowing your clinical and breath test data to be used for research Who may not be able to join: - No...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07149519 · University of Sao Paulo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇧🇷 BR

**Who might be able to join this trial:** - You are a woman between 18 and 50 years old who wants to take part in this clinical trial - You are willing to participate voluntarily and are comfortable being randomly assigned to any one of the three treatment groups in the study - You agree to not participate in any other...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07168434 · Biocodex Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 11 October 2026
🇵🇹 PT🇪🇸 ES

**Who might be able to join this trial:** - You are aged 18 to 65 years old (male or female) - You have been diagnosed with Irritable Bowel Syndrome (IBS) — any type *except* the constipation-dominant type — based on recognised medical criteria (called Rome IV) - Your IBS symptoms are rated at a moderate-to-severe leve...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07176078 · Universitair Ziekenhuis Brussel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇧🇪 BE

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with Irritable Bowel Syndrome (IBS) by a doctor using a standard set of diagnostic guidelines, and whose IBS symptoms are rated as moderate to severe on a recognised symptom scoring scale - People who h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07235215 · The President Stanisław Wojciechowski State University of Applied Scie... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇵🇱 PL

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) using a specific questionnaire from the World Global Gastroenterology Organization - Your IBS symptoms are rated at 175 points or higher on a standard IBS symptom severity scoring system (confirm with trial site) **...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07235228 · The President Stanisław Wojciechowski State University of Applied Scie... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇵🇱 PL

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) using a specific questionnaire from the World Global Gastroenterology Organization - Your IBS has been assessed as medium or severe using a standard IBS scoring system (a score of 175 points or higher) **Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07261826 · Chen QiYi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with one of the specific diseases this trial is studying. - You are 3 years old or older. - You have already received at least one Fecal Microbiota Transplantation (FMT) treatment, which is a procedure where stool from a healthy donor is used to help resto...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07283341 · Children's Hospital of Philadelphia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** *If joining as a "Case" (child with IBS):* - The child is between 8 and 18 years old (male or female) - The child has been diagnosed with irritable bowel syndrome (IBS) - A parent or guardian agrees to take part, and the child also agrees to take part *If joining as a "Contro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07309601 · Region Skane Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇸🇪 SE

Who might be able to join this trial: - People who have been diagnosed with irritable bowel syndrome (IBS) - People who have already had genetic testing related to genes that control the production of certain digestive enzymes (called sucrase-isomaltase), as part of a previous study involving a low-starch and low-sugar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07319078 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2030
🇸🇪 SE

Who might be able to join this trial: - The child or adolescent must be between 8 and 17 years old - Basic blood and stool tests must have already been completed (including inflammation markers, a celiac antibody test called TGA, a full blood count, and a stool test called fecal calprotectin) - A doctor must have confi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07360938 · Indiana University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a pro-inflammatory disease, specifically Type 2 Diabetes, Inflammatory Bowel Disease (IBD), or End-Stage Renal Disease (kidney failure) - You are able to sign a consent form agreeing to take part and allowing your health information to be used for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07421011 · Valenta Pharm JSC Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇷🇺 RU

**Who might be able to join this trial:** - Healthy volunteers aged 18 to 45 years (inclusive) who identify as Caucasian - People confirmed to be in good health, with no significant abnormalities found during medical history review, physical examination, lab tests, or other checks outlined in the study protocol - Peop...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07481422 · University of Rijeka Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 March 2027
🇭🇷 HR

**Who might be able to join this trial:** - You are between 18 and 65 years old - Your IBS symptoms are rated as moderate to severe based on a standard symptom scoring test (a score above 175 on the IBS-Symptom Severity Score) - Your symptoms have not improved enough after trying common IBS treatments, such as certain...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07494968 · University of Michigan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) — including the diarrhea, constipation, or mixed type - You do not have unexplained warning signs such as rectal bleeding, unexplained weight loss, pain at night, or diarrhea that wakes you from sleep — or if you do...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07517029 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇮🇹 IT

**Who might be able to join this trial:** This trial has three separate groups. You may qualify for one of the following: **Group 1 – People with post-infectious IBS (PI-IBS):** - You are 18 years old or older - You have been diagnosed with a specific type of IBS that developed after a gut infection, confirmed using...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07519395 · GlaxoSmithKline Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 9 March 2027
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 80 years old (inclusive) - You have been diagnosed with a type of irritable bowel syndrome that causes diarrhea (IBS-D) or a mixed type with both diarrhea and constipation (IBS-M), based on recognised diagnostic guidelines called Rome IV criteria - Your IBS...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07540312 · PGP Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign a written consent form agreeing to take part in the trial. - You weigh at least 50 kg (about 110 lbs) and have a body mass index (BMI) between 18 and 40. - You have been diagnosed with Irritable Bowel Syndrome (IBS) — specifically the constipa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07545759 · Eli Lilly and Company Phase 2 · 10 countries Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇧🇪 BE🇨🇦 CA🇨🇳 CN🇩🇪 DE🇯🇵 JP🇲🇽 MX🇵🇱 PL🇪🇸 ES +2 more

**Who might be able to join this trial:** - You have been diagnosed with a type of Irritable Bowel Syndrome that mainly causes diarrhea (IBS-D), meaning more than 25% of your bowel movements are very loose or watery, and fewer than 25% are hard or lumpy - During the 2 weeks before joining, your average worst daily bel...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07545772 · Eli Lilly and Company Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇧🇪 BE🇨🇦 CA🇨🇳 CN🇯🇵 JP🇲🇽 MX🇪🇸 ES🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a type of irritable bowel syndrome that mainly causes constipation (IBS-C), where most of your stools are hard or lumpy and very few are loose or watery - During a screening period before the trial starts, you kept a daily diary showing that your wors...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07581756 · The First Affiliated Hospital of Soochow University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 60 years old - People who have been diagnosed with diarrhoea-predominant irritable bowel syndrome (IBS-D) according to a standard set of diagnostic guidelines called Rome IV criteria - People who have had recurring abdominal pain at least once a week ov...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07584278 · Sahlgrenska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2031
🇸🇪 SE

**Who might be able to join this trial:** - You have been diagnosed with Irritable Bowel Syndrome (IBS) using a specific set of diagnostic guidelines called ROME V criteria - Your IBS symptoms are rated at a certain level of severity (a score of 75 or above on a standard IBS symptom scale — confirm with trial site) - Y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07584473 · University of Palermo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇮🇹 IT

**Who might be able to join this trial:** - You are a family member (relative) of someone who has been diagnosed with Celiac Disease - You are over 18 years old - You currently experience symptoms similar to Irritable Bowel Syndrome or functional digestive problems (such as bloating, stomach pain, or discomfort), as we...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07591584 · Kiwi Health Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 October 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 years or older - People whose gas and bloating symptoms scored 55 or higher on a specific validated symptom questionnaire called the PROMIS Gastrointestinal Gas and Bloating scale - People whose stomach pain scored 55 or higher on a specific validated symptom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07635394 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 April 2026
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 70 years old - You have been diagnosed with Irritable Bowel Syndrome (IBS) based on a standard set of medical guidelines called the Rome IV criteria - Your IBS symptoms are rated as mild to moderate based on a standard symptom scoring tool Who may not be a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07646834 · Tang-Du Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are right-handed, between 18 and 60 years old, and have completed more than 6 years of schooling - You have been diagnosed with Irritable Bowel Syndrome (IBS) according to specific medical guidelines (called Rome IV criteria), meaning you have had symptoms for at least 6...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07656623 · Institute of Gastroenterology and Hepatology, Vietnam Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇻🇳 VN

**Who might be able to join this trial:** - You have a medical reason to need both an upper digestive tract camera test (endoscopy) and a bowel camera test (colonoscopy) - You have been diagnosed with a type of irritable bowel syndrome with diarrhea (IBS-D), confirmed using a specific set of international guidelines ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07688044 · David Reed Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2030
🇨🇦 CA

**Who might be able to join this trial:** - Adults between 18 and 70 years old who have been diagnosed with Irritable Bowel Syndrome (IBS) based on recognised medical guidelines (Rome IV or V criteria) - People whose belly pain scores above a certain level, as measured by a standard questionnaire called PROMIS (a score...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Irritable Bowel Syndrome. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

The Gut Foundation covers IBS as part of its broader work on digestive health.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.